News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• May 5, 2005

  Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
• Apr 26, 2005

  Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
• Apr 20, 2005

  Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
• Apr 18, 2005

  Patent Infringement Suit Against Insmed Dismissed
• Apr 13, 2005

  FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Mar 16, 2005

  Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004
• Mar 15, 2005

  Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16
• Mar 15, 2005

  Insmed Announces Completion of $35 Million Financing
• Mar 10, 2005

  FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Feb 22, 2005

  Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download